META’s settlement is more important as a legal overhang clearance than as an operating event. The market may treat the payment as the price of admission to keep the core ad machine intact, but the more subtle effect is a longer-run constraint on engagement mechanics: any incremental friction on youth time-spent is a small near-term revenue headwind, yet it also lowers the odds of a harsher regulatory remedy later. That asymmetry generally favors the incumbent versus smaller social platforms that lack META’s compliance budget and legal optionality.

NVDA into earnings is a classic expectation-vs-durability setup, not a simple growth print. The market has already internalized strong AI demand; the bigger risk is that a clean beat still fails to justify the multiple if management does not confirm a second-half acceleration in capex and margins. A miss on guidance or gross margin would likely hit the entire AI hardware complex first, with semis like SMCI, AMD, and the SOXX ETF vulnerable to de-rating even if underlying end-demand remains intact.

RVMD is the cleaner idiosyncratic upside: approval validates the biology, but the commercial path depends on how many patients are actually molecularly tested and how quickly community oncologists switch from entrenched chemo norms. The consensus risk is overestimating near-term revenue and underestimating the time needed for diagnosis adoption, reimbursement, and combination-data readouts. The real monetization window is 6-18 months, not days; if early scripts or NCCN adoption disappoint, the stock can give back a meaningful fraction of the approval pop.